Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...
Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly ...
The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex ...
Vertex Pharmaceuticals Inc. hit a major milestone on Thursday when the U.S. Food and Drug Administration approved its ...
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...
Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...
In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...
(Reuters) -The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...